Key result
Modeling shows frequent low-dose aspirin beats higher daily doses for suppressing COX-1 in accelerated platelet turnover.
Why the study?
To characterize the determinants of the extent and duration of platelet COX-1 inhibition by aspirin and design precision dosing in patients with accelerated platelet turnover or reduced drug bioavailability.
Does precision dosing of aspirin (e.g., multiple daily doses) improve COX-1 inhibition in conditions of accelerated platelet turnover or reduced bioavailability compared to standard once-daily dosing?
Does precision dosing of aspirin (e.g., multiple daily doses) improve COX-1 inhibition in conditions of accelerated platelet turnover or reduced bioavailability compared to standard once-daily dosing?
A physiologically based pharmacokinetic/pharmacodynamic model demonstrates that reducing the dosing interval of aspirin is superior to increasing the once-daily dose for achieving adequate COX-1 inhibition in conditions with accelerated platelet turnover.
Answers are grounded in this paper and cite their sources.
Does not support changing aspirin dosing in practice; hypothesis-generating for trials of more frequent low-dose regimens in accelerated platelet turnover.
A computational approach involving mathematical modeling and in silico experiments was used to characterize the determinants of extent and duration of platelet cyclooxygenase (COX)-1 inhibition by aspirin and design precision dosing in patients with accelerated platelet turnover or reduced drug bioavailability. To this purpose, a recently developed physiologically-based pharmacokinetics (PK) and pharmacodynamics (PD) model of low-dose aspirin in regenerating platelets and megakaryocytes, was used to predict the main features and determinants of platelet COX-1 inhibition. The response to different aspirin regimens in healthy subjects and in pathological conditions associated with alterations in aspirin PK (i.e., severely obese subjects) or PD (i.e., essential thrombocytemya patients), were simulated. A model sensitivity analysis was performed to identify the main processes influencing COX-1 dynamics. In silico experiments and sensitivity analyses indicated a major role for megakaryocytes and platelet turnover in determining the extent and duration of COX-1 inhibition by once-daily, low-dose aspirin. They also showed the superiority of reducing the dosing interval vs increasing the once-daily dose in conditions of increased platelet turnover, while suggested specific dose adjustments in conditions of possible reduction in drug bioavailability. In conclusion, the consistency of our model-based findings with experimental data from studies in healthy subjects and patients with essential thrombocythemia supports the potential of our approach for describing the determinants of platelet inhibition by aspirin and informing precision dosing which may guide personalized antithrombotic therapy in different patient populations, especially in those under-represented in clinical trials or in those associated with poor feasibility.
No takes yet. Share an insight, caveat, or question.
Giaretta et al. (2022) studied Healthy subjects, essential thrombocythemia, severe obesity. Aspirin vs. Standard once-daily dosing was evaluated on Platelet COX-1 inhibition and serum thromboxane B2 (sTXB2) levels. Physiologically based pharmacokinetic and pharmacodynamic modeling demonstrated that reducing the dosing interval of low-dose aspirin is superior to increasing the once-daily dose for suppressing COX-1 activity in conditions of accelerated platelet turnover.
Synapse has enriched 10 related papers. Consider them for comparative context: